Two potentially novel biomarkers of hypoxia in ovarian cancer were selected – angiopoietin like protein 4 (ANGPTL4, up-regulated in both A2780 and A2780cis in response to hypoxia exposure) and human epidermal growth factor receptor 3 (HER3, up-regulated in A2780cis compared to A2780, and in hypoxic A2780 compared to normoxic A2780 while down-regulated in the A2780cis ‘hypoxic only’ response to cisplatin. This evidence concerns the gene ANGPTL4 and ovarian carcinoma.